Pharmaceutical Regulatory and Compliance Congress Regulator Roundtable Virginia Gibson Assistant U.S. Attorney.

Slides:



Advertisements
Similar presentations
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
Advertisements

Geriatric Practice: Challenges for Technology Peter A. Boling, MD Professor of Medicine Virginia Commonwealth University.
Basic Nursing: Foundations of Skills & Concepts Chapter 6 LEGAL RESPONSIBILITIES.
Consumer Safety and Drug Regulations
Clarity, consent and coverage for research-related injuries 6 th Annual Columbia University IRB Conference Boston, MA Patrick Taylor Children’s Hospital.
DAVID R. HOFFMAN Assistant U. S. Attorney 615 Chestnut Street Suite 1250 Philadelphia, PA Phone: (215) Fax: (215)
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
Capturing and Reporting Adverse Events in Clinical Research
1 District of Columbia Medical Assistance Administration Expedited Prior Authorization Pharmacy Guidance NOTE: As of October 1, 2008, the Medical Assistance.
Introduction to Regulation
John Naim, PhD Director Clinical Trials Research Unit
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Chapter 22 Regulatory & Advisory Agencies Copyright 2003, Elsevier Science (USA). All rights reserved. No part of this product may be reproduced or transmitted.
Clarity, consent and coverage for research-related injuries 6 th Annual Columbia University IRB Conference Boston, MA Patrick Taylor Children’s Hospital.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Pharmacy Compounding Legislation and Implementation AFDO 118th Annual Educational Conference Susan Laska Deputy Director Office of Medical Products & Tobacco.
Long Term Care: Medicare Prescription Drug Coverage in Institutions and Our Communities Larry Kocot Vanessa Duran.
Formulary IHE Pharmacy meeting - Den Haag 1. IHE Pharmacy white paper Formularies in the pharmaceutical practice Formularies as set of data in softwares.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
Good Clinical Practice GCP
Pharmacy and Therapeutics Committee
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 3 Drug Regulation, Development, Names, and Information.
Health Science/Research Policy Group II. Problem Statement Safety and effectiveness of prescription drugs in a real-world environment are uncertain because.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
HSP progress in Taiwan 2009 Benjamin I. Kuo, MD, DrPH, CIP Secretariat, Joint Institutional Review Board.
Open Payments Act AKA the ‘Sunshine Act’ Open Payments Act AKA the ‘Sunshine Act’ Public Postings of Physician Ownership, Investments, & Transfers of Value.
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
VANDERBILT-INGRAM CANCER CENTER CLINICAL TRIALS SHARED RESOURCES (CTSR) Jennifer S. Novia INFO 643 March 6, 2011.
PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM JIM SHEEHAN(EDPA)
New Faculty Orientation August 22, 2012 UAMS Research Support Center Director: Tom Wells (501)
Role of the Oncology Research Team Carmen B. Jacobs, RN, OCN, CCRP.
PSYCHOTROPIC / PSYCHOACTIVE DRUGS Presented by: Jun Hernandez, R.N. Prepared by: Rhonda Anderson, RHIA.
Top Healthcare Industry Issues
Health Care Distribution, Ch. 7. United States Gross Domestic Product (GDP) in 2002 was 10 trillion dollars  1.6 trillion of it was spent on health care.
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
Pharmaceutical Services Guidance Training CFR § , (a)(b)(1) F425.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
The Problematic Incentives of Government Regulation: Examples from Hairdresser Licensing and the FDA Presentation by Prof. Howard Baetjer Econ 640, April.
Pharmacy Administrator: Manager / Adminstrator for Pharmacies Research Leader for: oUoUniversities oHoHealth Insurance oPoPharmaceutical Companies.
National Health Expenditures as a Share of Gross Domestic Product (GDP) FIGURE 7.1 Between 2001 and 2011, health spending is projected to grow 2.5 percent.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
ASPECTS AFFECTING THE HOSPITAL OPERATION Financial Financial Operational Operational Administrative Administrative Clinical Clinical Safety Safety.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Copyright © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 8 Healthcare Delivery Systems.
Results: The Staff Safety Assessment Survey Lisa Lubomski, PhD April 11, 2013.
1 Patient Safety In China Gao Xinqiang 23 June 2014.
Preventing Errors in Medicine
1 Pharmacy Management and Cost-Containment: Pharmaceutical Fraud Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio
© 2009 Cengage Learning. All Rights Reserved. Regulating Hospitals.
FEDERAL ENFORCEMENT OF MINIMUM QUALITY STANDARDS James G. Sheehan Associate United States Attorney
미국의 마약류 관리제도 - FDA 와 NIDA 의 조직 및 업무 현황 의약품평가부 이선희.
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Chapter 2 Ethical and Legal Issues
How to Put Together an IDE Application
Vendor Management Monitoring performance of contracted clinical services at the UCONN Health Center.
Jennifer S. Novia INFO 643 March 6, 2011
PHARMA AUDIOCONFERENCE An Analysis of the HHS OIG Draft Compliance Program Guidance for the Pharmaceutical Industry Overview of Draft CPG Michael P.
Legal Aspects Affecting the Administration of Medications
Recovery Residences - Florida
Community and Primary Care Grants
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
January 10, 2006 D. McCarty (Mac) Thornton
Tobey Clark, Director*, Burlington USA
Compounded Drugs and Lack of Premarket FDA-Approval
Chapter 8 Healthcare Delivery Systems
Presentation transcript:

Pharmaceutical Regulatory and Compliance Congress Regulator Roundtable Virginia Gibson Assistant U.S. Attorney

Quality Of Care Issues Courts recognizing FCA as cause of action for poor quality care Prosecutors are finding ways to address gaps in law: –Kickbacks –False Statements –Failure to report events to FDA It’s about Medical judgment and patient choice

PBMs and Quality of Care Incentives for Drug Switching Manufacturer Pricing to PBM PBM Formulary Services Preferred Formularies HMO Formulary Who is making the decision: Calls to Physicians Calls to Pharmacists Prescription Cancellation Prescription Decisions in Best interest of patients

Institutional Quality of Care Nursing Homes and Hospitals affected by nursing shortage; Hospitals and medical errors: Medication administration Infection control Chemical restraints Medically unnecessary services Kensington Hospital: Unlicensed physicians, Kickbacks for staff privileges and for lab and cardiac services– lack of medical necessity Tenet in Redding CA:Unnecessary Cardiac Procedures - $54 million: August 03

Q of C in Clinical Research Protocols Phase II Trials for FDA Approval Patient Informed Consent Kickbacks for participation Trials run by MARKETING Dept., Not Medical Liaison Dept of Manufacturer Failure to Report Adverse Events in Trials

Q of C in Medical Devices USA v. Guidant: Failed to report Malfuinction of ancure device for abdominal aortic aneurisms. 12 Deaths. $92.4 criminal and civil penalties – June 03 USA v. Dentsply: Failure to report adverse events in dental cement $800,000 – March 03

Drug Manufacturing and Compounding Manufacturer 1.Adverse Event Reports and 2. Polymorphism in drug substances Reports of Variant Forms in Mfg process Storage Delivery Pharmacist Compounding : Courtney pharmacist who diluted chemotherapy drugs No adverse Event Reporting FDA 2002 Guidance on Compounding Thojpson v. Western States Medical Center struck down Compounding section of FDAMA of 97 State/ Federal Inspections